AMP-activated protein kinase activation ameliorates eicosanoid dysregulation in high-fat-induced kidney disease in mice

Anne Emilie Declèves, Anna V. Mathew, Aaron M. Armando, Xianlin Han, Edward A. Dennis, Oswald Quehenberger, Kumar Sharma

Research output: Contribution to journalArticle

Abstract

High-fat diet (HFD) causes renal lipotoxicity that is ameliorated with AMP-activated protein kinase (AMPK) activation. Although bioactive eicosanoids increase with HFD and are essential in regulation of renal disease, their role in the inflammatory response to HFD-induced kidney disease and their modulation by AMPK activation remain unexplored. In a mouse model, we explored the effects of HFD on eicosanoid synthesis and the role of AMPK activation in ameliorating these changes. We used targeted lipidomic profiling with quantitative MS to determine PUFA and eicosanoid content in kidneys, urine, and renal arterial and venous circulation. HFD increased phospholipase expression as well as the total and free pro-inflammatory arachidonic acid (AA) and anti-inflammatory DHA in kidneys. Consistent with the parent PUFA levels, the AA- and DHA-derived lipoxygenase (LOX), cytochrome P450, and nonenzymatic degradation (NE) metabolites increased in kidneys with HFD, while EPA-derived LOX and NE metabolites decreased. Conversely, treatment with 5-aminoimidazole-4-carboxamide-1-β-D-furanosyl 5'-monophosphate (AICAR), an AMPK activator, reduced the free AA and DHA content and the DHA-derived metabolites in kidney. Interestingly, kidney and circulating AA, AA metabolites, EPA-derived LOX, and NE metabolites are increased with HFD; whereas, DHA metabolites are increased in kidney in contrast to their decreased circulating levels with HFD. Together, these changes showcase HFD-induced pro- and anti-inflammatory eicosanoid dysregulation and highlight the role of AMPK in correcting HFD-induced dysregulated eicosanoid pathways.

Original languageEnglish (US)
Pages (from-to)937-952
Number of pages16
JournalJournal of lipid research
Volume60
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

AMP-Activated Protein Kinases
Eicosanoids
Kidney Diseases
High Fat Diet
Nutrition
Chemical activation
Fats
Metabolites
Kidney
Arachidonic Acid
Lipoxygenase
Degradation
Anti-Inflammatory Agents
Aminoimidazole Carboxamide
Phospholipases
Cytochrome P-450 Enzyme System
Modulation
Urine

Keywords

  • adenosine 5′-monophosphate
  • adenosine 5′-monophosphate-activated protein kinase
  • AICAR
  • chronic kidney disease
  • high-fat diet
  • obesity

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Cell Biology

Cite this

AMP-activated protein kinase activation ameliorates eicosanoid dysregulation in high-fat-induced kidney disease in mice. / Declèves, Anne Emilie; Mathew, Anna V.; Armando, Aaron M.; Han, Xianlin; Dennis, Edward A.; Quehenberger, Oswald; Sharma, Kumar.

In: Journal of lipid research, Vol. 60, No. 5, 01.05.2019, p. 937-952.

Research output: Contribution to journalArticle

Declèves, Anne Emilie ; Mathew, Anna V. ; Armando, Aaron M. ; Han, Xianlin ; Dennis, Edward A. ; Quehenberger, Oswald ; Sharma, Kumar. / AMP-activated protein kinase activation ameliorates eicosanoid dysregulation in high-fat-induced kidney disease in mice. In: Journal of lipid research. 2019 ; Vol. 60, No. 5. pp. 937-952.
@article{ad11d753a56042baa30518d27581f425,
title = "AMP-activated protein kinase activation ameliorates eicosanoid dysregulation in high-fat-induced kidney disease in mice",
abstract = "High-fat diet (HFD) causes renal lipotoxicity that is ameliorated with AMP-activated protein kinase (AMPK) activation. Although bioactive eicosanoids increase with HFD and are essential in regulation of renal disease, their role in the inflammatory response to HFD-induced kidney disease and their modulation by AMPK activation remain unexplored. In a mouse model, we explored the effects of HFD on eicosanoid synthesis and the role of AMPK activation in ameliorating these changes. We used targeted lipidomic profiling with quantitative MS to determine PUFA and eicosanoid content in kidneys, urine, and renal arterial and venous circulation. HFD increased phospholipase expression as well as the total and free pro-inflammatory arachidonic acid (AA) and anti-inflammatory DHA in kidneys. Consistent with the parent PUFA levels, the AA- and DHA-derived lipoxygenase (LOX), cytochrome P450, and nonenzymatic degradation (NE) metabolites increased in kidneys with HFD, while EPA-derived LOX and NE metabolites decreased. Conversely, treatment with 5-aminoimidazole-4-carboxamide-1-β-D-furanosyl 5'-monophosphate (AICAR), an AMPK activator, reduced the free AA and DHA content and the DHA-derived metabolites in kidney. Interestingly, kidney and circulating AA, AA metabolites, EPA-derived LOX, and NE metabolites are increased with HFD; whereas, DHA metabolites are increased in kidney in contrast to their decreased circulating levels with HFD. Together, these changes showcase HFD-induced pro- and anti-inflammatory eicosanoid dysregulation and highlight the role of AMPK in correcting HFD-induced dysregulated eicosanoid pathways.",
keywords = "adenosine 5′-monophosphate, adenosine 5′-monophosphate-activated protein kinase, AICAR, chronic kidney disease, high-fat diet, obesity",
author = "Decl{\`e}ves, {Anne Emilie} and Mathew, {Anna V.} and Armando, {Aaron M.} and Xianlin Han and Dennis, {Edward A.} and Oswald Quehenberger and Kumar Sharma",
year = "2019",
month = "5",
day = "1",
doi = "10.1194/jlr.M088690",
language = "English (US)",
volume = "60",
pages = "937--952",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "5",

}

TY - JOUR

T1 - AMP-activated protein kinase activation ameliorates eicosanoid dysregulation in high-fat-induced kidney disease in mice

AU - Declèves, Anne Emilie

AU - Mathew, Anna V.

AU - Armando, Aaron M.

AU - Han, Xianlin

AU - Dennis, Edward A.

AU - Quehenberger, Oswald

AU - Sharma, Kumar

PY - 2019/5/1

Y1 - 2019/5/1

N2 - High-fat diet (HFD) causes renal lipotoxicity that is ameliorated with AMP-activated protein kinase (AMPK) activation. Although bioactive eicosanoids increase with HFD and are essential in regulation of renal disease, their role in the inflammatory response to HFD-induced kidney disease and their modulation by AMPK activation remain unexplored. In a mouse model, we explored the effects of HFD on eicosanoid synthesis and the role of AMPK activation in ameliorating these changes. We used targeted lipidomic profiling with quantitative MS to determine PUFA and eicosanoid content in kidneys, urine, and renal arterial and venous circulation. HFD increased phospholipase expression as well as the total and free pro-inflammatory arachidonic acid (AA) and anti-inflammatory DHA in kidneys. Consistent with the parent PUFA levels, the AA- and DHA-derived lipoxygenase (LOX), cytochrome P450, and nonenzymatic degradation (NE) metabolites increased in kidneys with HFD, while EPA-derived LOX and NE metabolites decreased. Conversely, treatment with 5-aminoimidazole-4-carboxamide-1-β-D-furanosyl 5'-monophosphate (AICAR), an AMPK activator, reduced the free AA and DHA content and the DHA-derived metabolites in kidney. Interestingly, kidney and circulating AA, AA metabolites, EPA-derived LOX, and NE metabolites are increased with HFD; whereas, DHA metabolites are increased in kidney in contrast to their decreased circulating levels with HFD. Together, these changes showcase HFD-induced pro- and anti-inflammatory eicosanoid dysregulation and highlight the role of AMPK in correcting HFD-induced dysregulated eicosanoid pathways.

AB - High-fat diet (HFD) causes renal lipotoxicity that is ameliorated with AMP-activated protein kinase (AMPK) activation. Although bioactive eicosanoids increase with HFD and are essential in regulation of renal disease, their role in the inflammatory response to HFD-induced kidney disease and their modulation by AMPK activation remain unexplored. In a mouse model, we explored the effects of HFD on eicosanoid synthesis and the role of AMPK activation in ameliorating these changes. We used targeted lipidomic profiling with quantitative MS to determine PUFA and eicosanoid content in kidneys, urine, and renal arterial and venous circulation. HFD increased phospholipase expression as well as the total and free pro-inflammatory arachidonic acid (AA) and anti-inflammatory DHA in kidneys. Consistent with the parent PUFA levels, the AA- and DHA-derived lipoxygenase (LOX), cytochrome P450, and nonenzymatic degradation (NE) metabolites increased in kidneys with HFD, while EPA-derived LOX and NE metabolites decreased. Conversely, treatment with 5-aminoimidazole-4-carboxamide-1-β-D-furanosyl 5'-monophosphate (AICAR), an AMPK activator, reduced the free AA and DHA content and the DHA-derived metabolites in kidney. Interestingly, kidney and circulating AA, AA metabolites, EPA-derived LOX, and NE metabolites are increased with HFD; whereas, DHA metabolites are increased in kidney in contrast to their decreased circulating levels with HFD. Together, these changes showcase HFD-induced pro- and anti-inflammatory eicosanoid dysregulation and highlight the role of AMPK in correcting HFD-induced dysregulated eicosanoid pathways.

KW - adenosine 5′-monophosphate

KW - adenosine 5′-monophosphate-activated protein kinase

KW - AICAR

KW - chronic kidney disease

KW - high-fat diet

KW - obesity

UR - http://www.scopus.com/inward/record.url?scp=85065510126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065510126&partnerID=8YFLogxK

U2 - 10.1194/jlr.M088690

DO - 10.1194/jlr.M088690

M3 - Article

VL - 60

SP - 937

EP - 952

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 5

ER -